What is pathophysiology of Alzheimer?

['Yoká lokasa oyo']

Pathophysiologie ya Alzheimer ezali nini?

Pathophysiologie ya maladi ya Alzheimer (AD) ezali likambo moko ya mpasi oyo esangisi bokutani ya ba proteine ya mabe, inflammation, mpe dysfonctionnement ya neurones.

Bilembo mibale ya liboso ya maladi ya Alzheimer ezali plaque ya amyloïde-bêta (Aβ) mpe matonga ya ba neurones (NFT) na bɔɔngɔ.

Ba plaque ya beta-amyloïde ebotamaka ntango biteni ya proteine ya ebandeli ya amyloïde (APP) ekatanaka na ba enzymes mpo na kosala ba peptides ya Aβ.

Peptide oyo esanganaka mpe esalaka fibrille oyo ekoki kosila te oyo esanganaka na libanda ya neurone, mpe ebebisaka boyokani ya selile na selile mpe ememaka na liwa ya neurone.

Bato bakanisaka ete kobakisama ya baplakɛ ya Aβ ezali moko ya makambo ya liboso oyo ebandaka na maladi ya Alzheimer, mpe bakanisaka ete yango nde esalaka ete maladi yango ebebisa bɔɔngɔ.

Maboke ya neurofibrillary esalemaka ntango proteine tau ekomi hyperphosphorylée mpe ekomi ba filaments ya mabe na kati ya neurones.

Mwa biloko yango ebebisaka mosala ya malamu ya ba microtubules, oyo ezalaka na ntina mingi mpo na komema biloko oyo etongaka nzoto mpe biloko mosusu na kati ya neurone.

Nsukansuka, misisa yango oyo ekangamá ebomaka.

Kobima ya ba inflammation esalaka mpe mosala na pathophysiologie ya AD.

Systeme ya immunité eyanolaka na bokutani ya plaque ya Aβ mpe NFTs na kobimisama ya ba cytokines oyo epesaka maladi, oyo ekoki kobakisa mbeba na ba neurones.

Lisusu, ezali na bilembo oyo emonisi ete stress ya oxydation, dysfonctionnement ya mitochondria, mpe kobeba ya métabolisme ya glucose esalaka ete maladi ya Alzheimer ezala.

Makambo yango ekoki kosala ete baselile yango ebimisa lisusu makasi te mpe ekufa.

Na mobimba, maladi ya Alzheimer ezali na makambo mingi oyo esalaka ete moto akóma kobulungana mpe abosana makambo mingi.

['Makambo oyo ezali na buku yango']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Koboya: makambo ya monganga']

['Site oyo ezali kaka mpo na koteya mpe koyebisa bato makambo ya monganga, kasi ezali te mpo na kopesa toli to toli ya monganga.']

['Makambo oyo ezali na site yango esengeli te kosalelama mpo na koyeba maladi to kosalisa yango, mpe baoyo balingi kozwa toli ya monganga basengeli kotuna yango epai ya monganga oyo ayebi mosala yango malamu.']

['Tosengi na yo oyeba ete réseau neuronal oyo epesaka biyano na mituna, ezalaka mpenza malamu te soki ezali na makambo ya mituya. Na ndakisa, motango ya bato oyo bazali na maladi moko boye.']

['Sololá ntango nyonso na monganga to na moto mosusu oyo ayebi kosalisa maladi na yo. Koboya toli ya monganga te to kozela te mpo otángi likambo moko na site oyo. Soki okanisi ete ozali na maladi oyo esengeli kosalisa yo nokinoki, bengá 911 to kende na lopitalo ya pene. Site oyo to ndenge oyo ozali kosalela yango ezali na boyokani te na monganga ná moto oyo azali kosalisa yo.']

["Kozanga ndingisa: droit d'auteur"]

['Mobeko ya Copyright ya Milenere ya 1998, 17 U.S.C. § 512 (DMCA) epesi nzela na bakomi ya mikanda oyo bakanisi ete biloko oyo ezali na Internet ezali kobebisa lotomo na bango na kolanda mibeko ya copyright ya Etats-Unis. ']

['Soki ondimi na motema malamu ete makambo to biloko oyo ezali na site Internet to na ba service na biso ezali kobuka mibeko na yo, yo (to moto oyo azali na mokumba ya kobatela yo) okoki kotindela biso mokanda mpo na kosɛnga ete tólongola makambo to biloko yango to tópekisa yo kokɔta na yango. ']

['Basengeli kotinda bansango na mokanda na nzela ya email (tala na "Kotindelana" mpo na adresse ya email). ']

['Mibeko ya DMCA esengi ete mokanda na yo ya kofunda mbeba ya copyright ezala na makambo oyo elandi: (1) kolimbola mosala oyo ezali na droit ya copyright oyo bazali kofunda ete ebebisami; (2) kolimbola makambo oyo bazali kofunda ete ebebisi mpe makambo oyo ekoki mpo na kosalisa biso na koyeba esika makambo yango ezali; (3) makambo ya kosolola na yo, ata mpe adrɛsi na yo, nimero ya telefone mpe adrɛsi ya e-mail; (4) mokanda oyo okomi ete ondimi na motema malamu ete makambo oyo ozali kofunda ete ebebisami epesami nzela te na nkolo ya droit ya copyright, to na agent na ye, to na mibeko nyonso; ']

['(5) mokanda oyo okomi, oyo okotya sinyatili na yango mpo na komonisa ete makambo oyo okomaki ezali solo mpe ete ozali na lotomo ya kolandela lotomo ya babimisi oyo bazali koloba ete ebebisami; ']

['mpe (6) sinyatili ya moto oyo azali na lotomo ya kosala yango to ya moto oyo azali na lotomo ya kosala na nkombo na ye. ']

['Soki otye makambo nyonso te oyo ezali awa na likolo, yango ekoki kosala ete likambo na yo eumela.']

['Ndenge ya kosolola']

['Tosengi otindela biso email na motuna to likanisi nyonso.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.